| Current Price | $47.23 | Mkt Cap | $90.2B |
|---|---|---|---|
| Open | $48.20 | P/E Ratio | 19.74 |
| Prev. Close | $47.23 | Div. (Yield) | $2.01 (4.2%) |
| Daily Range | $47.23 - $48.25 | Volume | 1,286,399 |
| 52-Wk Range | $46.05 - $48.25 | Avg. Daily Vol. | 2,570,848 |
The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.
| Current Price | $47.23 | Mkt Cap | $90.2B |
|---|---|---|---|
| Open | $48.20 | P/E Ratio | 19.74 |
| Prev. Close | $47.23 | Div. (Yield) | $2.01 (4.2%) |
| Daily Range | $47.23 - $48.25 | Volume | 1,286,399 |
| 52-Wk Range | $46.05 - $48.25 | Avg. Daily Vol. | 2,570,848 |
The best Bull and Bear pitches based on recency and number of recommendations.
I am a long term investor who appreciates high dividends. Everything I have seen from GSK indicates a company that while struggling currently, has a good long term outlook. They pay a 5% + dividend and management is bullish on their ability to… More
GSK is revising Avandia product label to reflect negative events such as myocardial ischemia. Since there is no reduction in cardiovascular risks for diabetics, this reduces the long term outlook for the profitablity of this drug product and GSK.
Read the most recent pitches from players about GSK.
Recs
MaestroFool
(87.66)
Submitted: 8/7/2018 8:46:54 PM :
Start Price:
$39.09
NYSE:GSK Score:
-5.60
Facing the threat of generic Advair, but also a lot of debt on the balance sheet, forcing GSK to put a lot of their profits toward interest payments. Yet their dividend is one of the highest among their industry peers. This is great for shareholders hanging on for the dividend but not such great news for the long-term growth of the stock. Therefore, underperform.
Recs
DLandress79
(38.01)
Submitted: 7/24/2018 2:08:05 PM :
Start Price:
$38.70
NYSE:GSK Score:
+4.94
A PART OF MY "LONG" MIX
Recs
TMFGBudwell
(22.33)
Submitted: 10/30/2017 6:29:53 AM :
Start Price:
$33.10
NYSE:GSK Score:
+14.76
Improving fundamentals, new management.
Find the members with the highest scoring picks in GSK.
niwhsa (77.92) Score: +174.52
The Score Leader is the player with the highest score across all their picks in GSK.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| niwhsa | 77.92 | 11/20/2008 |
|
3Y | $19.14 | +146.76% | +321.28% | +174.52 | 0 Comment | |
| stockpickeraz | 27.44 | 1/16/2009 |
|
5Y | $20.59 | +129.40% | +296.50% | +167.09 | 0 Comment | |
| lwc123 | < 20 | 1/8/2009 |
|
3Y | $22.11 | +113.62% | +271.15% | +157.53 | 0 Comment | |
| stoneyg72 | 86.96 | 4/1/2009 |
|
3W | $17.68 | +167.08% | +312.60% | +145.51 | 0 Comment | |
| longterm007 | 68.23 | 10/31/2008 |
|
5Y | $21.77 | +116.94% | +254.44% | +137.50 | 0 Comment | |
| TRGoodvsEvil | 99.25 | 7/6/2009 |
|
5Y | $20.00 | +136.10% | +271.49% | +135.39 | 0 Comment | |
| MIKEP75731 | 38.04 | 5/22/2009 |
|
5Y | $19.18 | +146.22% | +273.28% | +127.06 | 1 Comment | |
| janiceelaine | < 20 | 10/6/2008 |
|
3Y | $23.77 | +98.69% | +214.85% | +116.15 | 0 Comment | |
| PurePwnage | 99.41 | 11/27/2009 |
|
5Y | $24.64 | +91.65% | +203.34% | +111.69 | 0 Comment | |
| Durp | 93.71 | 9/15/2006 |
|
3W | $28.59 | +65.19% | +165.98% | +100.79 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
